reglab/housing_qa huggingface dataset:
NJ Rev Stat § 24:6J-5 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6J-5 - Overdose prevention information.

24:6J-5 Overdose prevention information.  5. a. (1) A prescriber or other health care practitioner who prescribes or dispenses an opioid antidote in accordance with subsection a. of section 4 of P.L.2013, c.46 (C.24:6J-4), and a pharmacist who dispenses an opioid antidote pursuant to subsection a. of section 4 of P.L.2013, c.46 (C.24:6J-4) or section 1 of P.L.2017, c.88 (C.45:14-67.2), shall ensure that overdose prevention information is provided to the recipient. The overdose prevention information shall include, but need not be limited to: information on opioid overdose prevention and recognition; instructions on how to perform rescue breathing and resuscitation; information on opioid antidote dosage and instructions on opioid antidote administration; information describing the importance of calling the 911 emergency telephone service for assistance with an opioid overdose; and instructions for appropriate care of a person believed to be experiencing an opioid overdose after administration of the opioid antidote.  (2) (Deleted by amendment, P.L.2021, c.152). b. (1) (Deleted by amendment, P.L.2021, c.152). (2) The dissemination of overdose prevention information shall be documented by the prescribing or dispensing health care practitioner or dispensing pharmacist in the patient's medical record or another appropriate record, log or other similar recordkeeping location. c. In order to facilitate the dissemination of overdose prevention information in accordance with this section, the Commissioner of Human Services, in consultation with the Department of Health and Statewide organizations representing physicians, advanced practice nurses, or physician assistants, and organizations operating community-based programs, sterile syringe access programs, or other programs which address medical or social issues related to substance use disorders, may develop training materials in video, electronic, or other appropriate formats, and disseminate these materials to health care practitioners. The Commissioner of Human Services may make the materials available to the general public through the Internet website of the Department of Human Services, with such modifications as may be appropriate to adapt the materials for use by persons who are not health care practitioners. The commissioner shall ensure the materials are available in English, Spanish, and any other language that the commissioner determines is the first language of a significant number of people who are likely to be prescribed or dispensed an opioid antidote in accordance with subsection a. of section 4 of P.L.2013, c.46 (C.24:6J-4) or dispensed an opioid antidote pursuant to section 1 of P.L.2017, c.88 (C.45:14-67.2).  L.2013, c.46, s.5; amended 2015, c.10, s.3; 2021, c.152, s.4.
NJ Rev Stat § 24:6J-6 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6J-6 - Awarding of grants.

24:6J-6 Awarding of grants.  6. a. The Commissioner of Human Services may award grants, based upon any monies appropriated by the Legislature, to create or support local opioid overdose prevention, recognition, and response projects. County and municipal health departments, correctional institutions, hospitals, and universities, as well as organizations operating community-based programs, substance abuse programs, syringe access programs, or other programs which address medical or social issues related to drug addiction may apply to the Department of Human Services for a grant under this section, on forms and in the manner prescribed by the commissioner. b. In awarding any grant, the commissioner shall consider the necessity for overdose prevention projects in various health care facility and non-health care facility settings, and the applicant's ability to develop interventions that will be effective and viable in the local area to be served by the grant. c. In awarding any grant, the commissioner shall give preference to applications that include one or more of the following elements: (1) prescription and distribution of naloxone hydrochloride or any other similarly acting drug approved by the United States Food and Drug Administration for the treatment of an opioid overdose; (2) policies and projects to encourage persons, including drug users, to call 911 for emergency assistance when they witness a potentially fatal opioid overdose; (3) opioid overdose prevention, recognition, and response education projects in syringe access programs, drug treatment centers, outreach programs, and other programs operated by organizations that work with, or have access to, opioid users and their families and communities; (4) opioid overdose recognition and response training, including rescue breathing, in drug treatment centers and for other organizations that work with, or have access to, opioid users and their families and communities; (5) the production and distribution of targeted or mass media materials on opioid overdose prevention and response; (6) the institution of education and training projects on opioid overdose response and treatment for emergency services and law enforcement personnel; and (7) a system of parent, family, and survivor education and mutual support groups. d. In addition to any moneys appropriated by the Legislature, the commissioner may seek money from the federal government, private foundations, and any other source to fund the grants established pursuant to this section, as well as to fund on-going monitoring and evaluation of the programs supported by the grants. L.2013, c.46, s.6.
NJ Rev Stat § 24:6J-7 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6J-7 - Opioid antidotes, recognized place of public access.

24:6J-7 Opioid antidotes, recognized place of public access.  6. a. To the extent funds are made available by the State for this purpose, a recognized place of public access shall obtain a supply of opioid antidotes pursuant to a standing order issued pursuant to section 4 of P.L.2013, c.46 (C.24:6J-4) or section 1 of P.L.2017, c.88 (C.45:14-67.2), which opioid antidotes shall be maintained in one or more secure and easily accessible locations for the purpose of administering the opioid antidote to any person who is reasonably believed to be experiencing an opioid overdose. Nothing in this section shall be construed to limit, restrict, or otherwise prohibit any other person or entity from obtaining, maintaining, distributing, or administering opioid antidotes as authorized under section 4 of P.L.2013, c.46 (C.24:6J-4) or any other provision of law. b. A recognized place of public access that acquires and maintains a supply of opioid antidotes pursuant to subsection a. of this section shall ensure that at least one employee or volunteer who regularly provides services at, through, or on behalf of the recognized place of public access has received training on the standardized protocols for the administration of an opioid antidote to a person who is reasonably believed to be experiencing an opioid overdose, the requirements for which training shall be established by the Commissioner of Human Services. The training and protocols shall follow best practices for low-threshold community use of opioid antidotes in recognized places of public access, and shall include the overdose prevention information described in subsection a. of section 5 of P.L.2013, c.46 (C.24:6J-5). The commissioner may require by regulation that more than employee or volunteer at a recognized place of public access complete the training required pursuant to this subsection. c. A recognized place of public access may, to the extent not otherwise prohibited by State or federal law, enter into an agreement with a community-based organization to distribute opioid antidotes on the premises of the recognized place of public access. 2021, c.152, s.6.
NJ Rev Stat § 24:6K-1 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6K-1 - Definitions relative to dispensing certain biological products.

24:6K-1 Definitions relative to dispensing certain biological products.  1. As used in this act: "Biological product" means a "biological product" as defined in subsection (i) of section 351 of the Public Health Service Act (42 U.S.C. s.262(i)), and refers to a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings. "Interchangeable" means "interchangeable" as defined in subsection (i) of section 351 of the Public Health Service Act (42 U.S.C. s.262(i)) and indicated as interchangeable by the federal Food and Drug Administration in the "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations," sometimes referred to as the "Purple Book." "Therapeutically equivalent" means a therapeutic equivalence rating of "A" has been listed by the federal Food and Drug Administration in the "Approved Drug Products with Therapeutic Equivalence Evaluations," sometimes referred to as the "Orange Book." L.2015, c.130, s.1.
NJ Rev Stat § 24:6K-2 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6K-2 - Link to current lists of all biological products.

24:6K-2 Link to current lists of all biological products.  2. The New Jersey State Board of Pharmacy shall maintain a link to the current list of all biological products determined by the federal Food and Drug Administration to be interchangeable pursuant to section 351 of the Public Health Service Act (42 U.S.C. s.262) on the Board of Pharmacy's Internet website. L.2015, c.130, s.2.
NJ Rev Stat § 24:6K-3 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6K-3 - Conditions for substitution.

24:6K-3 Conditions for substitution.  3. a. A pharmacist may substitute a biological product for a prescribed biological product, provided that the following conditions are met: (1) the authorized prescriber has not indicated that there shall be no substitution as set forth in section 8 of P.L.1977, c.240 (C.24:6E-7); and (2) the biological product to be substituted has been determined by the federal Food and Drug Administration to be: (a) interchangeable with the prescribed biological product; or (b) therapeutically equivalent to the prescribed biological product. b. If a pharmacist dispenses a biological product, the pharmacist or the pharmacist's designee shall, within five business days following the dispensing of the biological product, communicate to the prescriber the specific product provided to the patient, including the name of the product and the manufacturer. No communication shall be required under this subsection when: (1) there is no biological product that has been determined by the federal Food and Drug Administration to be either: (a) interchangeable with the product prescribed; or (b) therapeutically equivalent to the product prescribed; or (2) a refill prescription is not changed from the product dispensed on the prior filling of the prescription. c. The communication requirement under subsection b. of this section may be satisfied by making an entry in an interoperable electronic medical records system or an electronic pharmacy record that can be accessed electronically by the prescriber, or through the use of another electronic prescribing technology that can be accessed electronically by the prescriber. Entry into an electronic records system as described in this paragraph is presumed to provide notice to the prescriber. Otherwise, the communication may be conveyed using other electronic means, if available, or by facsimile. d. A pharmacist who substitutes a biological product in compliance with this section shall record, on the prescription label and record of dispensing, the product name and manufacturer of the biological product dispensed, followed by the words: "Substituted for" and the name of the biological product for which the prescription was written. e. The same recordkeeping requirements as apply to the dispensing of drugs shall apply to the dispensing of biological products. f. A pharmacist who substitutes a biological product in compliance with this section shall incur no greater liability in filling the prescription by dispensing the biological product than would be incurred in filling the prescription by dispensing the prescribed biological product. L.2015, c.130, s.3.
NJ Rev Stat § 24:6K-4 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6K-4 - Rules, regulations.

24:6K-4 Rules, regulations.  7. The Commissioner of Health and the Director of the Division of Consumer Affairs, pursuant to the "Administrative Procedure Act," P.L.1968, c.410 (C.52:14B-1 et seq.), may adopt rules and regulations necessary to implement the provisions of this act. L.2015, c.130, s.7.
NJ Rev Stat § 24:6L-1 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6L-1 - Short title.

24:6L-1 Short title.  1. This act shall be known and may be cited as the "Epinephrine Access and Emergency Treatment Act." L.2015, c.215, s.1.
NJ Rev Stat § 24:6L-2 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6L-2 - Findings, declarations relative to epinephrine auto-injectors.

24:6L-2 Findings, declarations relative to epinephrine auto-injectors.  2. The Legislature finds and declares that: a. Insect and food allergies are the leading cause of anaphylaxis, a life-threatening condition that is easily treatable with epinephrine, a medication only available via prescription; b. Individuals who are known to be at risk of anaphylaxis may carry emergency doses of epinephrine with them at all times. However, many individuals may not be aware of their allergy and therefore do not carry epinephrine medication; c. New Jersey offers a broad array of outdoor, cultural, and culinary experiences which may expose its citizens to different kinds of insects and foods for the first time;  d. Exposure to insects or food resulting in an allergic reaction may occur in settings, such as youth camps, where medical professionals or first responders are not available to provide emergency care for anaphylaxis; e. The State of New Jersey, at P.L.1997, c.368 (C.18A:40-12.5 et seq.) and P.L.2013, c.211 (C.18A:61D-11 et seq.), has already recognized the value of training non-medical professionals to administer this life-saving drug in K-12 educational settings and institutions of higher education when a medical professional is not physically present at the scene; and f. It is prudent to similarly provide members of the public who have completed an approved training course with the tools necessary to respond to emergency anaphylaxis situations when assistance from medical professionals and first responders is not readily available. L.2015, c.215, s.2.
NJ Rev Stat § 24:6L-3 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6L-3 - Definitions relative to epinephrine auto-injectors.

24:6L-3 Definitions relative to epinephrine auto-injectors.  3. As used in this act:  "Commissioner" means the Commissioner of Health. "Health care professional" means a licensed physician, physician assistant, advanced practice nurse, pharmacist, or other health care professional whose professional practice is regulated pursuant to Title 45 of the Revised Statutes and whose authorized scope of practice includes prescribing, dispensing, or administering medication, whether independently or through a joint protocol or standing order from a physician. L.2015, c.215, s.3.
NJ Rev Stat § 24:6L-4 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6L-4 - Authorization to administer.

24:6L-4 Authorization to administer.  4. a. Any person who has successfully completed an educational program approved by the commissioner pursuant to section 5 of this act to administer an epinephrine auto-injector device shall be issued a certificate of completion, which shall authorize the person to administer, maintain, and dispose of an epinephrine auto-injector device.  b. A licensed health care professional may prescribe or dispense an epinephrine auto-injector device, either directly or through a standing order, to a person authorized to administer, maintain, and dispose of the device pursuant to subsection a. of this section. c. An entity employing a person authorized to administer, maintain, and dispose of an epinephrine auto-injector device pursuant to subsection a. of this section may obtain, maintain, and make available to the authorized person epinephrine auto-injector devices consistent with such standards and protocols as the commissioner may establish by regulation. L.2015, c.215, s.4.
NJ Rev Stat § 24:6L-5 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6L-5 - Written standards, application procedures.

24:6L-5 Written standards, application procedures.  5. The commissioner shall establish written standards and application procedures for approval of educational programs for the safe administration of epinephrine using an auto-injector device. An educational program shall include training in the administration of epinephrine auto-injector devices, recognition of the symptoms of anaphylaxis, safe maintenance and storage of epinephrine auto-injector devices, and such other information as the commissioner deems necessary. L.2015, c.215, s.5.
NJ Rev Stat § 24:6L-6 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6L-6 - Immunity from civil liability, disciplinary action.

24:6L-6 Immunity from civil liability, disciplinary action.  6. a. A health care professional shall not, as a result of the professional's acts or omissions, be subject to any civil liability or any professional disciplinary action under Title 45 of the Revised Statutes for any act or omission which is undertaken in good faith in accordance with this act. b. A person authorized to administer, maintain, or dispose of an epinephrine auto-injector device under subsection a. of section 4 of this act who, in good faith and without fee, administers an epinephrine auto-injector device to a person who appears to be suffering from anaphylaxis or any other serious condition treatable with epinephrine shall not, as a result of the person's acts or omissions, be subject to any civil liability for administering the device consistent with this act.  c. An entity authorized to obtain, maintain, and make available epinephrine auto injector devices to a person employed by the entity pursuant to subsection c. of section 4 of this act shall not, as a result of the entity's acts or omissions, be subject to any civil liability for any act or omission which is undertaken in good faith in accordance with this act. d. A person or entity conducting an educational program approved by the commissioner as provided in section 5 of this act shall not be subject to any civil liability for any act or omission which is undertaken in accordance with this act. e. For the purposes of this section, good faith does not include willful misconduct, gross negligence, or recklessness. L.2015, c.215, s.6.
NJ Rev Stat § 24:6L-7 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6L-7 - Construction of act.

24:6L-7 Construction of act.  7. Nothing in this act shall be construed to: a. permit a person who has completed a training program pursuant to this act to perform the duties or fill the position of a licensed medical professional; b. prohibit the administration of an epinephrine auto-injector device by a person acting pursuant to a lawful prescription; c. prevent a licensed and qualified member of a health care profession from administering an epinephrine auto-injector device if the duties are consistent with the accepted standards of practice applicable to the member's profession; or d. violate the "Athletic Training Licensure Act," P.L.1984, c.203 (C.45:9-37.35 et seq.) in the event that a licensed athletic trainer administers epinephrine as authorized pursuant to this act. L.2015, c.215, s.7.
NJ Rev Stat § 24:6M-1 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6M-1 - Findings, declarations relative to drug donation.

24:6M-1 Findings, declarations relative to drug donation.  1. The Legislature finds and declares that the health of low-income persons in the State can be improved, and the cost to the State of providing health care to low-income persons can be reduced, through the establishment of one or more programs that provide for: the donation of unused over-the-counter drugs, prescription drugs, and administration supplies, which would otherwise be destroyed; and the redistribution of such unused drugs and administration supplies to those persons who are most in need. L.2017, c.254, s.1.
NJ Rev Stat § 24:6M-5 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6M-5 - Immunity from liability.

24:6M-5 Immunity from liability.  5. a. Any donor, redistributor, third-party intermediary, common carrier, contract carrier, governmental agency, including but not limited to the Department of Health and the board, pharmacy benefit manager, pharmacy services administration organization, health care coverage program, or other entity or person, including but not limited to volunteers, employees, officers, directors, owners, partners, managers, and members, who acts reasonably and in good faith, within the scope of a drug donation program, and in accordance with the provisions of this act, shall be: (1) immune from civil or criminal liability for any injury, death, or loss suffered by a person who is dispensed a donated drug or donated administration supplies under this act; and (2) exempt from any professional disciplinary action stemming from any act or omission associated with any activity pursuant to this act, including but not limited to, the donation, acceptance, repackaging, transportation, transfer, or dispensing of a donated drug or donated administration supplies. b. A drug manufacturer, wholesaler, or other entity participating in the supply chain of the donated drug or donated administration supplies who acts reasonably and in good faith, in accordance with the provisions of this act, and as otherwise required by law, shall be immune from civil or criminal liability for any injury, death, or loss to a person or property stemming from any act or omission in association with any activity pursuant to this act including but not limited to the donation, acceptance, repackaging, transportation, transfer, or dispensing of an over-the-counter drug or prescription drug that is manufactured or distributed by the drug manufacturer, wholesaler, or other entity and donated pursuant to this act, including any liability resulting from a failure to transfer or communicate product or consumer information or the expiration date of the donated drug. c. A redistributor who dispenses donated drugs or administration supplies that have been recalled shall be immune from civil or criminal liability for any injury, death or loss suffered by a person who is dispensed those drugs or administration supplies, provided that the redistributor was not notified of the recall by the donor, by another redistributor, or through other means, as provided in subsection f. of section 4 of this act. L.2017, c.254, s.5.
NJ Rev Stat § 24:6M-6 (2021)
2021 New Jersey Revised Statutes|Title 24 - Food and Drugs|Section 24:6M-6 - Construction of act.

24:6M-6 Construction of act.  6. The provisions of this act shall not be construed to restrict the use of drug samples by a health care professional who is licensed to prescribe drugs and devices during the course of the professional's duties at a health care facility or pharmacy. L.2017, c.254, s.6.